Abdul Wahid*, Amna Tariq, Yusra Khan and Abdul Ahad

Department of Medicine, Karachi medical and dental college, Pakistan

*Corresponding Author: Abdul Wahid, Department of Medicine, Karachi medical and dental college, Pakistan.

Received: November 06, 2024; Published: January 31, 2025

Ischemic stroke, the second leading cause of death globally, results from interrupted cerebral blood flow due to thrombosis or embolism. Key risk factors include diabetes, smoking, hyperlipidemia, and hypertension. It causes significant neuronal and glial cell damage symptoms include sudden unilateral weakness, numbness, diplopia, slurred speech, ataxia, and non-orthostatic vertigo. Neurons in the ischemic core undergo cell death, while those in the penumbra show various stress responses. Increased blood-brain barrier permeability allows immune cells to infiltrate, which can release both protective and harmful factors affecting brain tissue [1].

References

1. Qin C., et al. “Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions”. Signal Transduction and Targeted Therapy1 (2006): 215.
2. Li BH., et al. “Different Doses of Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: A Network Meta-Analysis”. Frontiers in Neurology 13 (2022): 884267.
3. Shah K., et al. “Causes, predictors, and timing of early neurological deterioration and symptomatic intracranial hemorrhage after administration of IV tPA”. Neurocritical care 1 (2020): 1-7.
4. Maïer B., et al. “Intracranial hemorrhage after reperfusion therapies in acute ischemic stroke patients”. Frontiers in Neurology 11 (2020): 599908.
5. Amlie-Lefond C., et al. “Risk of intracranial hemorrhage following intravenous tPA (tissue-type plasminogen activator) for acute stroke is low in children”. Stroke 2 (2020): 542-548.
6. Maïer B., et al. “Intracranial hemorrhage after reperfusion therapies in acute ischemic stroke patients”. Frontiers in Neurology 11 (2020): 599908.
7. Anderson P. “Bleeding Risk Clarified in Patients with Ischemic Stroke Receiving tPA”. Medscape (2024).

Citation

Citation: Abdul Wahid., et al. “"Risk and Efficacy of tPA in Acute Ischemic Stroke: Implications of Antiplatelet Therapy and Hemorrhagic Complications"”. Acta Scientific Neurology 8.2 (2025): 13-14.

Copyright

Copyright: © 2025 Abdul Wahid., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.